Life sciences investment
Science, Innovation and Technology Committee
Closed
Inquiry
With MSD cancelling its £1 billion ongoing manufacturing site in Kings Cross, AstraZeneca pausing its £200 million investment in its Cambridge site, and the latter upgrading its US listing, the Science, Innovation and Technology Committee is launching a call for evidence on UK life sciences competitiveness. This follows an initial …
Read more
1
Oral session
4
Letters
1
Event
Activity timeline 5 events
4 Feb
2026
2026
20 Jan
2026
2026
19 Dec
2025
2025
19 Dec
2025
2025
28 Oct
2025
2025
Oral evidence
Oral evidence sessions 1 session
28 Oct 2025
View on parliament.uk
Life sciences investment; Innovation showcase
Dr Sam Roberts · NICE
Dr Zubir Ahmed MP · Department of Health and Social Care
Emily Hyett · Yoti
Steve Bates · Office for Life Sciences
The Lord Vallance of Balham KCB · Department for Science, Innovation and Technology
Correspondence 4 letters
4 Feb 2026
Correspondence from Minister of State for Science, Innovation, Research and Nuclear, re: UK-US life sciences deal, 30 January 2026
Parliament page
20 Jan 2026
Correspondence from Chair to Secretary of State for Department for Science, Innovation and Technology, re: UK-US life sciences deal, 19 January 2026
Parliament page
19 Dec 2025
Correspondence from Chair to Secretary of State for Department for Science, Innovation and Technology and Secretary of State for Department of Health and Social Care, re: Life sciences investment, 16 December 2025
Parliament page
19 Dec 2025
Correspondence from Minister for Science, Research and Innovation and Parliamentary Under-Secretary of State at the Department of Health and Social Care, re: Life sciences investment, 1 December 2025
Parliament page